Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8555 Results for "
binding
" in MedChemExpress (MCE) Product Catalog:
Products (8555)
8555 Results for "binding" in MCE Product Catalog:
Cat. No.: HY-B0110S
CAS No.: 1542211-40-4
Synonyms: SHB 331-d6; WL 70-d6
Gestodene-d6 (SHB 331-d6; WL 70-d6) is the deuterated-labeled Gestodene (HY-B0110). Gestodene is an orally active synthetic progestogen compound of the 19-nortestosterone class. Gestodene binds with high affinity to the progesterone receptor, inhibits 5α-reductase, binds to androgen and aldosterone receptors, and inactivates CYP3A. Gestodene acts as a positive allosteric modulator of PAR1, enhances PAR1-mediated signaling pathways, and is capable of increasing the activation potency of PAR1-AP toward PAR1, thereby promoting ERK1/2 phosphorylation, receptor internalization, cell morphological changes, and human platelet aggregation. Gestodene and its A-ring reduced metabolites promote the proliferation, differentiation, and mineralization of neonatal rat osteoblasts. Gestodene itself has no binding capacity for estrogen receptors, and this osteogenic activity depends on intracellular metabolism to generate A-ring reduced products with estrogen-like agonistic activity. Gestodene is useful for research on diseases related to progesterone secretion and diseases related to thrombosis .
Cat. No.: HY-N2593R
CAS No.: 32507-66-7
Cat. No.: HY-W753897
Synonyms: SHB 331-d7; WL 70-d7
Gestodene-d7 (SHB 331-d7; WL 70-d7) is the deuterated-labeled Gestodene (HY-B0110). Gestodene is an orally active synthetic progestogen compound of the 19-nortestosterone class. Gestodene binds with high affinity to the progesterone receptor, inhibits 5α-reductase, binds to androgen and aldosterone receptors, and inactivates CYP3A. Gestodene acts as a positive allosteric modulator of PAR1, enhances PAR1-mediated signaling pathways, and is capable of increasing the activation potency of PAR1-AP toward PAR1, thereby promoting ERK1/2 phosphorylation, receptor internalization, cell morphological changes, and human platelet aggregation. Gestodene and its A-ring reduced metabolites promote the proliferation, differentiation, and mineralization of neonatal rat osteoblasts. Gestodene itself has no binding capacity for estrogen receptors, and this osteogenic activity depends on intracellular metabolism to generate A-ring reduced products with estrogen-like agonistic activity. Gestodene is useful for research on diseases related to progesterone secretion and diseases related to thrombosis .
Cat. No.: HY-L950
2,787 compounds
Seven-membered rings are privileged medium-sized scaffolds with distinct twist-chair conformations and greater 3D diversity than five- and six-membered rings. Their flexible conformations allow induced-fit protein binding and precise pharmacophore positioning. They also modulate Fsp³, pKa and logP to enhance solubility and permeability. Azepanes, oxepanes and benzodiazepines serve as bioisosteres for hit discovery against GPCRs, ion channels and kinases.
Widely found in plant and microbial alkaloids, seven-membered heterocycles show excellent biocompatibility and target affinity. They underpin many approved drugs for CNS, cancer and infectious diseases, including diazepam, imipramine and carbamazepine. Clinical candidates further highlight their unique value. However, high transannular strain and synthetic difficulty limit their availability, leaving them rare in standard screening libraries.
MCE 7 Membered Scaffold Library contains 2,792 structurally diverse, lead-like molecules covering azepanes, oxepanes, benzodiazepines and dibenzazepines. With varied substitutions, chiral centers and synthetic accessibility, it fills the shortage of medium-ring scaffolds. Ideal for HTS, virtual screening and SAR studies, these novel, patent-clear compounds offer a distinctive starting point for drug discovery in CNS disorders, oncology, antivirals and challenging targets such as PPIs.
Cat. No.: HY-L018
458 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.
MCE designs a unique collection of 458 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.
Cat. No.: HY-P75830
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P75832
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P75833
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Rat
Source:
HEK293
Cat. No.: HY-P75834
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Rat
Source:
HEK293
Cat. No.: HY-P76989
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Canine
Source:
HEK293
Cat. No.: HY-P76990
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL13RA2; IL-13R Subunit Alpha-2; Interleukin 13 Receptor Subunit Alpha 2; IL-13R-Alpha-2; CD213a2; IL-13RA2; IL-13R; Interleukin-13 Receptor Alpha 2 Variant; IL13BP; Interleukin 13 Receptor Alpha 2 Chain; CT19; Interleukin 13 binding Protein; Interleukin-
Species:
Canine
Source:
HEK293
Cat. No.: HY-P701809
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MARK4; FLJ90097; Prev. MARKL1; Non-Specific Serine/Threonine Protein Kinase; MAP/Microtubule Affinity-Regulating Kinase 4; Epididymis Secretory Sperm binding Protein; KIAA1860; MARK4 Serine/Threonine Protein Kinase; PAR-1D; MARKL1L; MAP/Microtubule Affinity-Regulating Kinase Like 1; MARK4L; Nbla00650; MARK4S; Microtubule Affinity Regulating Kinase 4; MAP/Microtubule Affinity-Regulating Kinase-Like 1
Species:
Human
Source:
E. coli
Cat. No.: HY-P85607
Synonyms: Bag 1; BAG family molecular chaperone regulator 1; BAG-1; BAG1; BAG1_HUMAN; BCL 2 Associated Athanogene 1; BCL 2 associated athanogene; BCL 2 binding athanogene 1; Bcl-2-associated athanogene 1; BCL2 associated athanogene 1; BCL2 associated athanogene; Glucocorticoid receptor-associated protein RAP46; HAP1; Haptoglobin; RAP 46; RAP46.
Cat. No.: HY-P705931
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: DUSP22; JNK-Stimulatory Phosphatase-1; Dual Specificity Phosphatase 22; MAP Kinase Phosphatase X; JKAP; LMW-DSP2; JSP1; LMWDSP2; MKPX; MKP-X; Low Molecular Weight Dual Specificity Phosphatase 2; JSP-1; JNK Pathway Associated Phosphatase; Homolog Of Mouse Dual Specificity Phosphatase LMW-DSP2; VHX; Epididymis Secretory Sperm binding Protein; Mitogen-Activated Protein Kinase Phosphatase X; JNK-Stimulating Phosphatase 1; Dual Specificity Protein Phosphatase 22
Species:
Human
Source:
E. coli
Cat. No.: HY-P812030A
Synonyms: MED27; Mediator Complex Subunit 27; CRSP34; TRAP37; CRSP8; MED3; Cofactor Required For Sp1 Transcriptional Activation, Subunit 8, 34kDa; Mediator Of RNA Polymerase II Transcription Subunit 27; Transcriptional Coactivator CRSP34; P37 TRAP/SMCC/PC2 Subunit; CRSP Complex Subunit 8; Cofactor Required For Sp1 Transcriptional Activation Subunit 8; Epididymis Secretory Sperm binding Protein; NEDSCAC; CRAP34
Cat. No.: HY-P84973
Synonyms: BLR1; MDR15; BLR 1 antibody; BLR1 antibody; Burkitt lymphoma receptor 1 antibody; Burkitt lymphoma receptor 1 GTP binding protein antibody; Burkitt lymphoma receptor 1; GTP binding protein; chemokine; C-X-C motif; receptor 5; antibody; C X C chemokine receptor type 5 antibody; C-X-C chemokine receptor type 5 antibody; CD 185 antibody; CD185 antibody; CD185 antigen antibody; Chemokine; C-X-C motif; receptor 5 antibody; Chemokine C X C motif receptor 5 antibody; Chemokine CXC motif receptor 5 antibody; Chemokine receptor 5 antibody; CXC chemokine receptor type 5 antibody; CXC R5 antibody; CXC-R5 antibody; CXCR 5 antibody; CXCR-5 antibody; Cxcr5 antibody; CXCR5_HUMAN antibody; MDR 15 antibody; MDR-15 antibody; MDR15 antibody; MGC117347 antibody; Monocyte derived receptor 15 antibody; Monocyte-derived receptor 15 antibody;
Cat. No.: HY-P85022
Synonyms: BLR1; MDR15; BLR 1 antibody; BLR1 antibody; Burkitt lymphoma receptor 1 antibody; Burkitt lymphoma receptor 1 GTP binding protein antibody; Burkitt lymphoma receptor 1; GTP binding protein; chemokine; C-X-C motif; receptor 5; antibody; C X C chemokine receptor type 5 antibody; C-X-C chemokine receptor type 5 antibody; CD 185 antibody; CD185 antibody; CD185 antigen antibody; Chemokine; C-X-C motif; receptor 5 antibody; Chemokine C X C motif receptor 5 antibody; Chemokine CXC motif receptor 5 antibody; Chemokine receptor 5 antibody; CXC chemokine receptor type 5 antibody; CXC R5 antibody; CXC-R5 antibody; CXCR 5 antibody; CXCR-5 antibody; Cxcr5 antibody; CXCR5_HUMAN antibody; MDR 15 antibody; MDR-15 antibody; MDR15 antibody; MGC117347 antibody; Monocyte derived receptor 15 antibody; Monocyte-derived receptor 15 antibody;
Cat. No.: HY-P86815
Synonyms: ATP/GTP binding protein antibody; Cleavage and polyadenylation factor I subunit 1 antibody; CLP 1 antibody; clp1 antibody; CLP1 cleavage and polyadenylation factor I subunit homolog antibody; CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae) antibody; CLP1, yeast, homolog of antibody; CLP1_HUMAN antibody; hClp1 antibody; Homolog of yeast CFIA subunit Clp1p antibody; ATP/GTP binding protein antibody; Cleavage and polyadenylation factor I subunit 1 antibody; CLP 1 antibody; clp1 antibody; CLP1 cleavage and polyadenylation factor I subunit homolog antibody; CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae) antibody; CLP1, yeast, homolog of antibody; CLP1_HUMAN antibody; hClp1 antibody; Homolog of yeast CFIA subunit Clp1p antibody; Polyadenylation factor Clp1 antibody; Polynucleotide kinase Clp1 antibody; Polyribonucleotide 5' hydroxyl kinase Clp1 antibody; Polyribonucleotide 5''-hydroxyl-kinase Clp1 antibody; Pre mRNA cleavage complex II protein Clp1 antibody; Pre-mRNA cleavage complex II protein Clp1 antibody;
Cat. No.: HY-108659
CAS No.: 202982-98-7
Research Areas:
NF340 is a P2Y11 receptor inhibitor with a pIC50 of 7.3-7.7 against human P2Y11 receptor, and it exhibits high selectivity over other P2Y family receptors. NF340 binds to the ATP-binding amino acid residues of the P2Y11 receptor to inhibit its activity, block nociceptive activity, and reduce spinal dorsal horn P2Y11 receptor upregulation induced by spinal nerve injury. NF340 attenuates the NFκB signaling pathway activated by IL-1β by decreasing IκBα phosphorylation, nuclear p65 accumulation, and NFκB promoter activity. NF340 inhibits IL-1β-induced pro-inflammatory cytokine expression, reduces intracellular ROS and 4-HNE levels, and suppresses IL-1β-induced matrix metalloproteinase expression in primary fibroblast-like synoviocytes. NF340 inhibits ATP-induced elevation of intracellular Ca 2+ concentration and cell migration in human hepatocellular carcinoma cells. NF340 can be used in the research of neuropathic pain, myocardial ischemia/reperfusion injury, inflammatory pain, rheumatoid arthritis, and hepatocellular carcinoma .
Cat. No.: HY-12888
CAS No.: 907543-25-3
Target:
Research Areas:
AZD5099 is an orally effective pyrrole amide inhibitor and antibacterial agent. AZD5099 shows over 10000-fold higher selectivity for bacterial type II topoisomerases than for human topoisomerase IIα, with a IC50 value of 0.032 μmol/L against Staphylococcus aureus GyrB, a IC50 of 0.760 μmol/L against Escherichia coli GyrB, a IC50 of 73 nM against Escherichia coli ParE, a Kd of 83.8 nmol/L for Staphylococcus aureus GyrB, and a IC50 of >50 μM against human topoisomerase IIα. AZD5099 inhibits rat Mrp2 ATPase activity, competitively binds to the ATP-binding site of bacterial type II topoisomerases, blocks enzyme activity, reduces bacterial DNA and RNA synthesis, disrupts DNA replication and transcription processes, and induces mitochondrial toxicity. AZD5099 exhibits activity against Gram-positive bacteria, fastidious Gram-negative bacteria and drug-resistant strains, reduces bacterial loads in mouse infection models, and has a low spontaneous resistance frequency. AZD5099 can be used in studies related to infections caused by Gram-positive bacteria and fastidious Gram-negative bacteria, methicillin-resistant Staphylococcus aureus infections, Streptococcus pneumoniae pulmonary infections, as well as Staphylococcus aureus and Escherichia coli infections .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
